Jenburkt Pharmaceuticals Ltd Share Price

Pharmaceuticals

BSE: 524731 Small Cap ISIN: INE354A01013

As on 18 July 2026 at 19:29 IST

₹1,187.85

+ 30.20

(2.61%)

Sell Buy

Over 1 Month

0.42%

Over 6 Months

7.19%

Over 1 Year

-8.59%

Over 3 Years

78.65%

Jenburkt Pharmaceuticals Ltd Summary

Close ₹1,157.65

Open ₹1,166.60

High ₹1,175

Low ₹1,149.95

Volume 749

Net Turnover (in Cr) ₹0.086

52Wk High ₹1,410

52Wk Low ₹944

52Wk High / Low

944

1,410

Jenburkt Pharmaceuticals Ltd Fundamentals

Key Financial Data

Market Cap (in Cr) ₹510.91

EPS (TTM) 85.23

Book Value (BV) 446.48

Div. Yield 1.79 %

P/E (TTM) 14.71

Price/Book Value 2.59

Delivery % 88.65 %

Face Value 10

Key Ratios

PE Ratio 13.93

PB Ratio 2.60

EV to Sales 2.81

PEG Ratio 0.59

ROA 17.94

ROE 20.25

Debt-Equity 0.01

Net Profit Margin 21.14

Operating Profit Margin 31.06

Jenburkt Pharmaceuticals Ltd Financials

Consolidated

Standalone

Yearly

Quarterly

Profit and Loss

No data available

Balance Sheet

No data available

Cash Flow

No data available

Profit and Loss

Particulars (in ₹ Cr.)	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Total Revenue	158.41	146.63	141.87	128.93	113.60
Total Expenses	114.48	111.46	109.01	99.06	91.96
Profit Before Tax	43.93	35.18	32.86	29.87	21.64
Profit After Tax	32.06	25.98	24.61	22.30	16.50
Operating Profit After Depreciation	44.39	35.45	33.23	30.31	22.12

Balance Sheet

Particulars (in ₹ Cr.)	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Fixed Assets	14.66	10.36	10.45	11.40	10.55
Total Non Current Assets	139.65	55.37	60.72	67.05	41.20
Total Current Assets	56.53	109.73	81.09	75.90	79.99
Total Assets	196.19	165.10	141.81	142.95	121.18
Total Shareholder's Fund	171.78	144.94	122.39	117.38	98.47

Cash Flow

Particulars (in ₹ Cr.)	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Net Cash From Operating Activities	27.91	8.12	17.05	9.27	19.45
Net Cash Used In Investing Activities	-17.04	-0.58	2.62	-1.20	-18.78
Net Cash Used In Financing Activities	-7.62	-7.08	-21.04	-5.53	-0.71

No data available

Particulars (in ₹ Cr.)	2026-03	2025-12	2025-09	2025-06	2025-03
Total Revenue	44.63	43.02	45.56	35.53	41.05
Total Expenses	30.38	35.60	32.46	26.57	30.19
Profit Before Tax	13.71	8.29	14.33	10.19	11.84
Profit After Tax	10.85	5.93	10.16	7.79	8.54
Operating Profit after Depreciation	18.60	9.24	15.18	11.02	12.74

Jenburkt Pharmaceuticals Ltd Technicals

Support and Resistance

S3 S2 S1 Pivot R1 R2 R3

S1 1,146.73

S2 1,135.82

S3 1,121.68

Pivot 1,160.87

R1 1,171.78

R2 1,185.92

R3 1,196.83

Moving Average

20 SMA 1,158.67

50 SMA 1,099.63

100 SMA 1,068.08

200 SMA 1,095.87

Jenburkt Pharmaceuticals Ltd Corporate Actions

Jenburkt Pharmaceuticals Ltd

₹18.0/Share

Announcement Date 11 Jul 2025

Record Date 11 Jul 2025

Div Yield 180%

AGM Date: 07 Sep 2021

AGM 07/09/2021 Outcome Of Board Meeting Held Today, I.E. 2Nd June, 2021 To schedule the Company's 36th Annual General Meeting on Tuesday, 07th September, 2021 Intimation for the closure of the Members'' register and share transfer books of the Company for the 36th AGM and dividend along with the cut off date for the eligibility of shareholders for e-voting.in relation to the AGM. (As per BSE Announcement Dated on 12/7/2021) Enclosed please find herewith a Scrutinizer''s Report on the AGM of the Company held on 7th September, 2021. Sub: Outcome of the 36th Annual General Meeting held on 7th September, 2021 and voting results of the AGM alongwith Scrutinizer''s Report. This is to inform you that the 36th Annual General Meeting (''AGM'') of the Company was held on Tuesday, 7th September, 2021 at 3.30 P.M. (IST) through Video Conferencing. Enclosed please find herewith an outcome and voting results of the AGM alongwith Scrutinizer''s Report. Proceedings of the 36th AGM held on 7th September, 2021. (As per BSE Announcement Dated on 8/9/2021) Jenburkt Pharmaceuticals Ltd has informed BSE regarding the details of Voting results of AGM, under Regulation 44(3) of SEBI (LODR) Regulations, 2015. (As Per BSE Announcement dated on 09.09.2021)

AGM Date: 29 Jul 2022

AGM 29.07.2022 The board of directors at their meeting held on 27th May2022, declared book closure and record date in connection with the 37th AGM to be held on 27th May, 2022. Outcome and Voting Results of the 37th Annual General Meeting of Jenburkt Pharmaceuticals Limited held on 29th July, 2022. Voting Results of the 37th Annual General Meeting of Jenburkt Pharmaceuticals Limited held on 29th July, 2022 and Scrutinizers'' Report Proceedings of the 37th AGM held on 29th July, 2022. Jenburkt Pharmaceuticals Ltd has informed BSE regarding the details of Voting results of AGM, under Regulation 44(3) of SEBI (LODR) Regulations, 2015. (As Per BSE Announcement Dated on 30/07/2022)

AGM Date: 26 Jul 2023

The Board of Directors of the Company, at their meeting held on 23rd May, 2023, fixed the book closure date starting from Thursday, 20th July, 2023 to Wednesday, 26th July, 2023 (both days inclusive) for the purpose of payment of dividend, as recommended in the same meeting. The Board has also, fixed the cut-off date as Wednesday, 19th July, 2023, for the purpose of determining the eligibility of Shareholders eligible for remote e-voting or e-voting during the 38th AGM, scheduled on Wednesday, 26th July, 2023. Pursuant to regulation 30 of the SEBI-LODR, we enclosed copies of advertisement published in newspapers viz. The Free Press Journal (English) and Navshakti (Marathi) on 01st July, 2023, respectively, regarding Notice of the 38th Annual General Meeting of the Members of the Company. (As Per BSE Announcement Dated on 01.07.2023) JENBURKT PHARMACEUTICALS LIMITED has informed BSE about Notice of Shareholders Meeting for Annual General Meeting. (As Per BSE Announcement Dated on 05.07.2023) Announcement under Regultion 30 (LODR)-proceedings of the 38th AGM of the Company held today, i.e. 26th July, 2023, through VC/OAVM. (As per BSE Announcement Dated on 26/07/2023) Appointment of an independent and non-executive director viz. Sumit A. Thakkar, at the 38th AGM of the Company held on 26.07.2023 (As Per BSE Announcement dated on 27.07.2023)

AGM Date: 30 Jul 2024

Outcome of Board Meeting Held on 28th May, 2024 Intimation of Book Closure date and Cut-off Date for the purpose of Payment of Dividend and Remote e-voting for 39th Annual General Meeting. (As Per BSE Announcement dated on 28.05.2024) Proceedings of the 39th Annual General Meeting held on Toady i.e. 30th July, 2024. (As per BSE Announcement Dated on 30/07/2024) Submission of Voting Results and Scrutinizer report for the 39th AGM of the Company held on 30th July, 2024. (As Per BSE Announcement Dated on: 31/07/2024)

AGM Date: 18 Jul 2025

To schedule the Company's 40th Annual General Meeting on Friday, 18 July 2025 to be held by Video Conferencing / Other Audio-Visual Means (VC/OAVM). Submission of the Annual Report for the FY 2024-25, containing Audited Financial Statements, Auditors Report and Directors Report and the Notice convening 40th Annual General Meeting of the Company. (As Per BSE Announcement Dated on 20/06/2025) Newspaper publication in pursuance of Rule 20(4) of the companies (Management and Administration) Rules, 2014, in connection with the 40th AGM of the Company. (As Per BSE Announcement Dated on 23.06.2025) Summary of the proceedings of the 40th Annual General Meeting of the Company held on 18th July, 2025. Submission of Consolidated Voting Results and Scrutinizer''s Report on all the resolutions as set out in the notice convening the 40th AGM of the Company held on 18th July, 2025. Appointment of Secretarial Auditor of the Company. Proceedings of the 40th Annual General Meeting of the Company held on today i.e. 18th July, 2025. (As per BSE Announcement Dated on 18/07/2025)

Jenburkt Pharmaceuticals Ltd Peer Comparison

Company	Price	Market Cap (in Cr)
Sun Pharmaceutical Industries Ltd	₹1,794.30	₹4,30,512.67
Divis Laboratories Ltd	₹6,651.25	₹1,76,569.79
Torrent Pharmaceuticals Ltd	₹4,570	₹1,54,669.57
Cipla Ltd	₹1,383	₹1,11,725.01
Zydus Lifesciences Ltd	₹1,105.65	₹1,11,254.26

Jenburkt Pharmaceuticals Ltd Top Mutal Funds Invested

No data available

Jenburkt Pharmaceuticals Ltd News

Board of Jenburkt Pharmaceuticals recommends final dividend

Of Rs 20.7 per share

06 May 2026, 09:44 am

Jenburkt Pharmaceuticals to hold AGM

On 4 September 2026

06 May 2026, 09:44 am

Jenburkt Pharmaceuticals to announce Quarterly Result

On 5 May 2026

29 Apr 2026, 10:06 am

Jenburkt Pharmaceuticals to announce Quarterly Result

On 3 February 2026

28 Jan 2026, 01:57 pm

Jenburkt Pharmaceuticals to hold board meeting

On 28 October 2025

04 Oct 2025, 10:06 am

Jenburkt Pharmaceuticals Ltd Stock Analysis

Annual revenue for Jenburkt Pharmaceuticals Ltd increased by 8.03% to ₹158.41 crore in FY 2025 from ₹146.63 crore in FY 2024.
Annual Net Profit for Jenburkt Pharmaceuticals Ltd increased by 23.42% to ₹32.06 crore in FY 2025 from ₹25.98 crore in FY 2024.
Promoter Shareholding in Jenburkt Pharmaceuticals Ltd decreased by 0.02% in the most recent quarter, from 46.65% in December 2025 to 46.64% in March 2026.
Jenburkt Pharmaceuticals Ltd delivered a 1-year return of -8.59% compared to the Nifty 50, which provided a return of -7.87% as of the last trading session.
Jenburkt Pharmaceuticals Ltd share price moved up by 2.61% from its previous close of INR ₹1,157.65. The latest Jenburkt Pharmaceuticals Ltd share price is INR ₹1,187.85.
Jenburkt Pharmaceuticals Ltd share price today has been at a low of 1,165.95 and a high of 1,189. Over the past 52 weeks, the Jenburkt Pharmaceuticals Ltd share price has seen a low of 944 and a high of 1,410.